全球诱导多功能细胞生产市场规模、份额、趋势和成长分析报告（2026-2034）

预计诱导多功能细胞生产市场将从 2025 年的 17,875.8 亿美元成长到 2034 年的 4,1499.4 亿美元，2026 年至 2034 年的复合年增长率为 9.81%。

由于人们对再生医学和细胞疗法的兴趣日益浓厚，全球诱导多功能细胞（iPS细胞）市场正经历显着增长。 iPS细胞是将成体细胞重编程为胚胎样的状态，并且能够分化成多种细胞类型。这项技术在疾病建模、药物筛检和组织再生方面具有巨大的潜力。干细胞生物学研究的日益活跃以及慢性疾病盛行率的上升正在推动市场的发展。

推动该市场发展的主要因素是iPS细胞在个人化医疗和先进治疗方法开发中的应用日益广泛。製药公司利用iPS细胞测试药物的毒性和疗效，降低后期临床试验失败的风险。政府的支持性法规、资助计画以及研究机构与生技公司之间的合作也促进了产能的提升。重编程技术的进步使整个过程更加高效且经济。

随着干细胞疗法临床试验的增加，预计未来市场将快速成长。自动化生产系统和标准化通讯协定的开发将进一步提升规模化生产能力。亚太地区生物技术基础设施的不断完善，使其成为一个极具潜力的市场。随着再生医学的普及，诱导多能干细胞（iPS细胞）生产市场有望实现持续的长期成长和创新。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球诱导性多功能细胞生产市场：依製程划分

• 市场分析、洞察与预测
• 手动iPS细胞生产过程
• 自动化iPS细胞生产工艺

第五章 全球诱导性多功能细胞生产市场：依工作流程划分

• 市场分析、洞察与预测
• 再程式化
• 细胞培养
• 细胞表征/分析
• 工程
• 其他的

第六章 全球诱导性多功能细胞生产市场：依产品分类

• 市场分析、洞察与预测
• 设备/器材
• 自动化平台
• 耗材和工具包
• 服务

第七章 全球诱导性多功能细胞生产市场：依应用划分

• 市场分析、洞察与预测
• 药物研发和药物发现
• 再生医学
• 毒理学测试
• 其他的

第八章 诱导多功能细胞生产的全球市场：依最终用途划分

• 市场分析、洞察与预测
• 研究和学术机构
• 生物技术和製药公司
• 医院和诊所

第九章 全球诱导性多功能细胞生产市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十一章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Lonza
  • Axol Bioscience Ltd
  • Evotec
  • Hitachi Ltd
  • Reprocell Inc
  • Merck KGaA
  • Reprocells Inc
  • Fate Therapeutics
  • Thermo Fisher Scientific Inc
  • StemCellsFactory III
  • Applied StemCells Inc

The Induced Pluripotent Stem Cells Production Market size is expected to reach USD 4149.94 Billion in 2034 from USD 1787.58 Billion (2025) growing at a CAGR of 9.81% during 2026-2034.

The Global Induced Pluripotent Stem Cells (iPSCs) Production Market is witnessing strong growth due to rising interest in regenerative medicine and cell-based therapies. iPSCs are adult cells that are reprogrammed to an embryonic-like state, allowing them to differentiate into various cell types. This technology offers significant potential in disease modeling, drug screening, and tissue regeneration. Increasing research activities in stem cell biology and the growing prevalence of chronic diseases are driving the market forward.

A major driver for this market is the expanding application of iPSCs in personalized medicine and advanced therapeutic development. Pharmaceutical companies are using iPSCs to test drug toxicity and efficacy, reducing the risk of failure in later clinical stages. Supportive government regulations, funding programs, and partnerships between research institutes and biotech firms are also accelerating production capabilities. Technological improvements in reprogramming methods have made the process more efficient and cost-effective.

Looking ahead, the market is expected to grow rapidly with increasing clinical trials involving stem cell therapies. The development of automated production systems and standardized protocols will further enhance scalability. Asia-Pacific is emerging as a strong region due to expanding biotechnology infrastructure. As regenerative medicine becomes more mainstream, the iPSCs production market is likely to see sustained long-term growth and innovation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Process

• Manual iPSC Production Process
• Automated iPSC Production Process

By Workflow

• Reprogramming
• Cell Culture
• Cell Characterization/Analysis
• Engineering
• Others

By Product

• Instruments/Devices
• Automated Platforms
• Consumables & Kits
• Services

By Application

• Drug Development & Discovery
• Regenerative Medicine
• Toxicology Studies
• Others

By End Use

• Research & Academic Institutes
• Biotechnology & Pharmaceutical Companies
• Hospitals & Clinics

COMPANIES PROFILED

• Lonza, Axol Bioscience Ltd, Evotec, Hitachi Ltd, Reprocell Inc, Merck KGaA, Reprocells Inc, Fate Therapeutics, Thermo Fisher Scientific Inc, StemCellsFactory III, Applied StemCells Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY PROCESS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Process
• 4.2. Manual iPSC Production Process Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Automated iPSC Production Process Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Workflow
• 5.2. Reprogramming Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cell Culture Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Cell Characterization/Analysis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Engineering Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY PRODUCT 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Product
• 6.2. Instruments/Devices Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Automated Platforms Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Consumables & Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY APPLICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Application
• 7.2. Drug Development & Discovery Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Regenerative Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Toxicology Studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY END USE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End Use
• 8.2. Research & Academic Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Biotechnology & Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Process
  • 9.2.2 By Workflow
  • 9.2.3 By Product
  • 9.2.4 By Application
  • 9.2.5 By End Use
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Process
  • 9.3.2 By Workflow
  • 9.3.3 By Product
  • 9.3.4 By Application
  • 9.3.5 By End Use
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Process
  • 9.4.2 By Workflow
  • 9.4.3 By Product
  • 9.4.4 By Application
  • 9.4.5 By End Use
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Process
  • 9.5.2 By Workflow
  • 9.5.3 By Product
  • 9.5.4 By Application
  • 9.5.5 By End Use
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Process
  • 9.6.2 By Workflow
  • 9.6.3 By Product
  • 9.6.4 By Application
  • 9.6.5 By End Use
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Lonza
  • 11.2.2 Axol Bioscience Ltd
  • 11.2.3 Evotec
  • 11.2.4 Hitachi Ltd
  • 11.2.5 Reprocell Inc
  • 11.2.6 Merck KGaA
  • 11.2.7 Reprocells Inc
  • 11.2.8 Fate Therapeutics
  • 11.2.9 Thermo Fisher Scientific Inc
  • 11.2.10 StemCellsFactory III
  • 11.2.11 Applied StemCells Inc